Medical Condition News

RSS

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Ohr Pharmaceutical today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

24 Sep 2012

Low levels of vitamin D associated with higher risk of heart attack and early death

New research from the University of Copenhagen and Copenhagen University Hospital shows that low levels of vitamin D are associated with a markedly higher risk of heart attack and early death. The study involved more than 10,000 Danes and has been published in the well-reputed American journal Arteriosclerosis, Thrombosis and Vascular Biology.

24 Sep 2012

RXi completes dosing in RXI-109 Phase 1 study for dermal scarring

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that dosing with their first drug in its first Phase 1 study, was completed last week.

24 Sep 2012

Marijuana and testicular cancer: an interview with Victoria Cortessis

This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).

24 Sep 2012

BioLineRx receives U.S. patent allowance for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) claiming the crystalline form of BL-1020, a first-in-class orally available treatment for schizophrenia.

24 Sep 2012

Cannabis Science commences CSTATI-1 preclinical studies in Squamous/BCCs, Kaposi's sarcoma

Cannabis Science, a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, is pleased to announce preclinical investigations being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

24 Sep 2012

Valeant purchases QLT’s Visudyne

Valeant Pharmaceuticals International, Inc. announced today that it has acquired Visudyne, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT Inc.

24 Sep 2012

Consuming fish with environmental pollutants can increase risk of cardiovascular diseases

Eat fish, but avoid fish with the most pollutants. This is the conclusion drawn by a group of researchers at Umeå University in Sweden after having weighed the risks of mercury content against the advantages of healthful fatty acids. The work was done as part of an international collaborative effort.

24 Sep 2012

$Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma$

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Cell Therapeutics, Inc. announced today that the phase 1 study data of its highly selective oral JAK2 inhibitor pacritinib, or SB1518, showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed/refractory lymphoma.

24 Sep 2012

Molecular similarity between one sub-type of breast cancer and ovarian cancer

A team of scientists with The Cancer Genome Atlas program reports their genetic characterization of 800 breast tumors, including finding some of the genetic causes of the most common forms of breast cancer, providing clues for new therapeutic targets, and identifying a molecular similarity between one sub-type of breast cancer and ovarian cancer.

24 Sep 2012

Interleukin-6 could affect hunger and satiety

Researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden, have identified a molecule in the immune system that could affect hunger and satiety. The researchers hope that new treatments for obesity will benefit from this finding.

24 Sep 2012

Novel genetic tools may shed new light in papillary thyroid carcinoma research

Next-generation sequencing analyses of the follicular variant of papillary thyroid carcinoma may elucidate the biological underpinnings and clinical behavior of an increasingly common disease, according to data presented at the 82nd ATA Annual Meeting in Québec City, Québec, Canada.

24 Sep 2012

Many survivors of young adult cancers avoid routine medical care due to cost barriers

Many survivors of adolescent and young adult cancers avoid routine medical care because it's too expensive, despite the fact that most have health insurance.

24 Sep 2012

Improvements in trauma care are urgently needed

With traumatic injuries claiming almost six million lives a year, improvements in care, including in the challenging areas of brain and bone injuries, and haemorrhage, are urgently needed.

24 Sep 2012

New technique allows cells to make terpenes

Scientists at The Scripps Research Institute have shown how to synthesize in the laboratory an important set of natural compounds known as terpenes. The largest class of chemicals made by living organisms, terpenes are made within cells by some of the most complex chemical reactions found in biology.

24 Sep 2012

Researchers identify subgroups of B cells in MYC-positive germinal centers

Germinal centers are sites in the organs of the lymphatic system, formed during the course of an immune response to infection, where B cells intensely proliferate and modify their DNA in order to produce antibodies specific for the pathogen. However, it is known that the vast majority of lymphomas derive from the B cells at the germinal centers.

24 Sep 2012

Vitamin D deficiency affects more Australians than previously thought

September marks the start of spring but new research reveals it is also the month when Australians’ vitamin D levels are at their lowest ebb.

24 Sep 2012

Boston Scientific receives regulatory approval to market RELIANCE 4-FRONT in Europe and Asia

Boston Scientific Corporation has received regulatory approval to market the RELIANCE 4-FRONT lead, its next generation implantable defibrillation lead now available in Europe and Asia. Defibrillation leads are insulated wires that connect an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator to the heart for treatment of heart failure and sudden cardiac arrest.

24 Sep 2012

Age 65 and above may be more accurate marker for prognosis of papillary thyroid cancer

Although age 45 is used to establish staging in well-differentiated papillary thyroid cancer using the American Joint Committee on Cancer and the International Union Against Cancer TNM Classification of Malignant Tumors (TNM) staging system, a new study presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada, suggests that > 65 may be a more accurate age marker for prognosis.

24 Sep 2012

New findings on how naked mole-rats adapt to acidic environments

Naked mole-rats evolved to thrive in an acidic environment that other mammals, including humans, would find intolerable. Researchers at the University of Illinois at Chicago report new findings as to how these rodents have adapted to this environment.

24 Sep 2012